Vincerx Pharma (VINC) Competitors $0.06 +0.01 (+21.24%) As of 06/12/2025 03:34 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VINC vs. NMTR, SYRS, ATXI, REVB, SRNE, BIOR, VIRX, BPTSY, HEPA, and MYMDShould you be buying Vincerx Pharma stock or one of its competitors? The main competitors of Vincerx Pharma include 9 Meters Biopharma (NMTR), Syros Pharmaceuticals (SYRS), Avenue Therapeutics (ATXI), Revelation Biosciences (REVB), Sorrento Therapeutics (SRNE), Biora Therapeutics (BIOR), Viracta Therapeutics (VIRX), Biophytis (BPTSY), Hepion Pharmaceuticals (HEPA), and MyMD Pharmaceuticals (MYMD). These companies are all part of the "pharmaceutical products" industry. Vincerx Pharma vs. Its Competitors 9 Meters Biopharma Syros Pharmaceuticals Avenue Therapeutics Revelation Biosciences Sorrento Therapeutics Biora Therapeutics Viracta Therapeutics Biophytis Hepion Pharmaceuticals MyMD Pharmaceuticals 9 Meters Biopharma (NASDAQ:NMTR) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, community ranking, valuation, risk and institutional ownership. Do institutionals & insiders hold more shares of NMTR or VINC? 22.3% of 9 Meters Biopharma shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 2.4% of 9 Meters Biopharma shares are owned by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts recommend NMTR or VINC? Vincerx Pharma has a consensus price target of $40.00, suggesting a potential upside of 67,927.21%. Given Vincerx Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Vincerx Pharma is more favorable than 9 Meters Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 9 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vincerx Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is NMTR or VINC more profitable? Vincerx Pharma's return on equity of -248.33% beat 9 Meters Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets 9 Meters BiopharmaN/A -584.97% -159.45% Vincerx Pharma N/A -248.33%-132.73% Does the media favor NMTR or VINC? In the previous week, Vincerx Pharma had 1 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 1 mentions for Vincerx Pharma and 0 mentions for 9 Meters Biopharma. Vincerx Pharma's average media sentiment score of 1.00 beat 9 Meters Biopharma's score of 0.00 indicating that Vincerx Pharma is being referred to more favorably in the news media. Company Overall Sentiment 9 Meters Biopharma Neutral Vincerx Pharma Positive Which has preferable valuation and earnings, NMTR or VINC? Vincerx Pharma is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/AVincerx PharmaN/AN/A-$40.16M-$20.600.00 Does the MarketBeat Community favor NMTR or VINC? 9 Meters Biopharma received 16 more outperform votes than Vincerx Pharma when rated by MarketBeat users. Likewise, 71.15% of users gave 9 Meters Biopharma an outperform vote while only 65.63% of users gave Vincerx Pharma an outperform vote. CompanyUnderperformOutperform9 Meters BiopharmaOutperform Votes3771.15% Underperform Votes1528.85% Vincerx PharmaOutperform Votes2165.63% Underperform Votes1134.38% Which has more risk & volatility, NMTR or VINC? 9 Meters Biopharma has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. SummaryVincerx Pharma beats 9 Meters Biopharma on 12 of the 15 factors compared between the two stocks. Get Vincerx Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VINC vs. The Competition Export to ExcelMetricVincerx PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$308K$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E Ratio0.008.6727.1419.96Price / SalesN/A262.53416.49157.63Price / CashN/A65.8538.2534.64Price / Book0.016.597.074.69Net Income-$40.16M$143.75M$3.23B$248.14M7 Day PerformanceN/A0.68%0.72%0.91%1 Month PerformanceN/A11.93%9.65%5.71%1 Year PerformanceN/A4.33%32.02%14.71% Vincerx Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VINCVincerx Pharma3.622 of 5 stars$0.06+21.2%$40.00+67,927.2%-99.6%$308KN/A0.0060Positive NewsShort Interest ↓Gap UpNMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220SYRSSyros Pharmaceuticals3.7561 of 5 stars$0.03+6.7%$3.33+10,316.7%-99.6%$859K$386K-0.01120Gap DownATXIAvenue Therapeutics1.8562 of 5 stars$0.25+14.7%N/A-91.9%$796KN/A0.014Gap DownREVBRevelation Biosciences0.4523 of 5 stars$0.82-3.2%N/A-97.8%$793KN/A0.0010Short Interest ↑High Trading VolumeSRNESorrento Therapeutics0.3522 of 5 stars$0.00-23.5%N/A-83.8%$717K$60.32M0.00800Gap DownBIORBiora Therapeutics1.7991 of 5 stars$0.14-1.4%$23.00+16,328.6%-98.1%$633K$892K-0.01120Upcoming EarningsVIRXViracta Therapeutics2.0112 of 5 stars$0.02-15.8%$1.75+11,263.6%-97.4%$612KN/A-0.0120Gap DownBPTSYBiophytisN/A$1.73flatN/A-82.2%$607KN/A0.0030Short Interest ↑HEPAHepion Pharmaceuticals1.2844 of 5 stars$0.04-27.0%N/A-99.9%$441KN/A-0.0120Short Interest ↓MYMDMyMD PharmaceuticalsN/A$0.16-3.1%N/A-91.4%$380KN/A0.006Gap UpHigh Trading Volume Related Companies and Tools Related Companies NMTR Competitors SYRS Competitors ATXI Competitors REVB Competitors SRNE Competitors BIOR Competitors VIRX Competitors BPTSY Competitors HEPA Competitors MYMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VINC) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vincerx Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vincerx Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
